Hello Regulatory Scientists,
Today, let’s dive into the journey of Kevzara (sarilumab) from receiving an FDA Complete Response Letter (CRL) to achieving approval. This case study provides valuable insights and lessons that can guide companies developing new drugs today.
Regulatory History and Initial Submission
Drug: Kevzara (sarilumab)
Mechanism of Action: IL-6 receptor antagonist, which helps reduce inflammation by blocking the activity of interleukin-6
Indication: Treatment of moderate to severe rheumatoid arthritis (RA)
Initial Submission Date: January 2016
The Complete Response Letter (CRL)
CRL Date: October 2016
CRL Concerns:
- Manufacturing Issues: The FDA raised concerns about deficiencies in the manufacturing process at the Le Trait facility in France.
- Quality Control: Issues related to ensuring the consistency and quality of the drug’s production.
Resubmission Strategy
Sanofi and Regeneron, the companies behind Kevzara, implemented a comprehensive strategy to address the FDA’s concerns:
- Facility Improvements: Made significant upgrades to the Le Trait manufacturing facility to address the identified deficiencies.
- Quality Control Enhancements: Implemented stricter quality control measures to ensure the consistency and quality of the drug’s production.
- Detailed Documentation: Provided extensive documentation to the FDA detailing the improvements made and how they addressed the concerns raised.
- Continuous FDA Engagement: Maintained open lines of communication with the FDA to ensure alignment on the resubmission strategy and clarify any outstanding questions.
Resubmission Date: January 2017
Outcome
Approval Date: May 2017
Kevzara was approved for the treatment of moderate to severe rheumatoid arthritis in patients who have had an inadequate response or intolerance to one or more disease-modifying antirheumatic drugs (DMARDs).
Lessons Learned
The journey of Kevzara from CRL to approval highlights several key lessons for drug developers:
- Addressing Manufacturing Issues: Ensuring that manufacturing facilities meet regulatory standards is crucial. Proactive upgrades and quality control measures can prevent setbacks.
- Thorough Documentation: Providing detailed documentation to demonstrate how issues have been resolved is essential for regulatory approval.
- Continuous FDA Engagement: Maintaining open and ongoing communication with the FDA helps align development efforts with regulatory expectations.
- Proactive Quality Control: Implementing stringent quality control measures ensures the consistency and reliability of the drug’s production.
Relevance for Current Drug Developers
For companies developing drugs today, the Kevzara case underscores the importance of strategic planning and meticulous attention to manufacturing processes in the regulatory process. Here are some takeaways to help avoid a CRL and achieve first-cycle approval:
- Thorough Pre-Submission Preparation: Ensure that all aspects of your submission, particularly manufacturing processes and quality control measures, meet FDA standards.
- Proactive Risk Management: Identify and address potential manufacturing issues early in the development process to prevent issues from arising during FDA review.
- Engage with the FDA Early and Often: Regular interactions with the FDA can provide valuable guidance and help steer the development process.
- Invest in Facility Upgrades: Prioritize the improvement of manufacturing facilities to meet regulatory standards and ensure high-quality production.
- Detailed Documentation: Provide comprehensive documentation to support the resolution of any identified issues.
By learning from the Kevzara resubmission experience, current drug developers can better navigate the regulatory landscape, avoid common pitfalls, and increase the likelihood of a successful first review cycle approval.
Stay diligent and strategic,
CERES Regulatory Services
